Implementation of international guidelines for the treatment of epileptic spasms, is challenging when access to adrenocorticotrophic hormone (ACTH) and vigabatrin is restricted, especially in Low and Middle Income Countries (LMIC). Oral corticosteroids are alternative interventions but evidence for the optimal agent, dose, duration, efficacy and long-term effects is lacking.
Introduction
Access to hormonal and synthetic adrenocorticotrophic hormone (ACTH) is limited in many regions of the world [1] . This report explores the evidence to support use of oral corticosteroids, namely prednisolone or prednisone, in comparison to ACTH and other agents in the management of children with epileptic spasms.
The incidence of childhood epilepsy is highest in the infantile period and epileptic spasms are the most common seizure type in this age period [2] .
Epileptic spasms are characterized by a brief contraction followed by a sustained tonic contraction of the neck, trunk, upper and lower legs and may be flexor, extensor or mixed [3] . They tend to occur in clusters, usually while awakening or just before sleep [4] . Spasms are frequently misdiagnosed with conditions such as colic, gastrooesophageal reflux and constipation, which results in delayed intervention [5] . The diagnosis of epileptic spasms is based on the semiology of the seizure and the interictal pattern of hypsarrhythmia on the EEG [6] . Hypsarrhythmia is defined as random high voltage slow waves accompanied by focal, multifocal or generalized spikes [7] . Variations from classic hypsarrhythmia are called modified hypsarrhythmia and may include focality, burst suppression, slow waves without spikes and partial preservation of the background [5] .
The incidence of epileptic spasms in high income countries range between 0.25 and 0.42 per 1000 live births per year, peak onset is between 4 and 6 months, with a slight male preponderance [8] . The term "epileptic spasms" replaced "infantile spasms", as the seizure type may persist or have the potential to develop beyond the infantile period [9] .
The United Kingdom Infantile Spasms Study (UKISS) found that the most common aetiologies for ES were hypoxic ischaemic encephalopathy (10%), chromosomal (8%), cerebral malformations (8%), cerebrovascular disease (8%), Tuberous Sclerosis Complex (TSC) (7%), periventricular leukomalacia or haemorrhage (5%) but in 33% no cause could be identified [10] . Data was collected from a high income resource equipped setting. Data is limited on epilepsy in Africa in general, especially from sub-Saharan Africa, and even less so for this specific seizure type. A study based in rural Uganda in 1997, found that 7 out of 440 children with epilepsy, had a history suggestive of "infantile spasms" [11] . However, this may be an underestimation, since lack of resources, such as EEG, made it challenging to make a syndromic diagnosis [11] .
Additional challenges facing Low and Middle Income Countries (LMIC) include greater numbers of aetiologies, such as perinatal asphyxia, which is associated with worse long term outcome [12] .
Epileptic spasms are difficult to treat and associated with a high morbidity, with up to 90% of patients having intellectual disability [5, 13] . The persistence of hypsarrhythmia appears to be associated with ongoing epileptic encephalopathy, as such it is important to treat this finding until there is resolution on the EEG [5] . This differs from standard approaches in the management of epilepsy, where treatment of clinical events is promoted. For infants with [14, 15] . According to the Cochrane review by Hancock et al hormonal treatment resolves spasms in more infants than vigabatrin, and if prednisolone or vigabatrin are used, high dose is recommended [16] . The lag time refers to the time taken between ES onset and intervention with treatment. Early cessation of spasms and a shorter lag time to treatment result in a reduced total duration of epileptic encephalopathy and resultant developmental delay [17] . Prolonged lag time and acquired aetiologies (e.g. HIE, postinfectious) in LMICs result in lower rates of spasm freedom compared to high income countries. This is further compounded by lack of health-seeking behaviour of parents, lack of awareness among health care professionals and inappropriate antiepileptic drug use [18] .
A systematic review of the literature was undertaken to establish the quality of evidence relating to the use of oral prednisolone and prednisone in the management of children with epileptic spasms. This review was driven by the need to develop a recommendation to standardize a safe and effective regimen using this product over other agents, such as ACTH and vigabatrin in LMICs, where access to these internationally recommended agents is lacking.
Systematic review
Using the MeSH terms "infantile spasms" and "prednisolone" and keywords "epileptic spasms", "treatment", "management", "prednisone" and "oral corticosteroids" in Pubmed, Web of Science, Scopus incl. Embase, Medline, Africa-Wide, Cinahl, Cochrane reviews and clinical trials.com a total of 114 studies were found between 1990 and 2017, n = 96 were excluded as they did not address the study question. There were n = 18 studies in total, n = 14 addressing the intervention and immediate outcome and n = 4 the long-term outcome [17, [19] [20] [21] . Search terms were broad to encompass any studies which utilised oral corticosteroids in the management of ES. Studies were critiqued for directness to the study question of "efficacy in the management of ES" and consistency in study methodology across studies to permit comparison of outcome data. Clinical human studies were included, as well as articles in English. Review articles were checked for additional papers not captured by the search. Quality of data was graded according to the American Academy of Neurology (AAN) practice parameters [15] . In accordance with AAN practice parameters, level A evidence recommendations are established as effective, ineffective or harmful, level B probably effective, ineffective or harmful, level C possibly effective, ineffective or harmful and level U data is inadequate or conflicting [15, 22] . Findings from the included studies are summarised in Table 1 .
Management of epileptic spasms
Standardized management protocols for infants with epileptic spasms have resulted in an increase of affected patients receiving recommended first-line treatment, with improved remission rates three months after diagnosis [23] . For children whose spasms result from aetiologies, excluding TSC, ACTH is the preferred first line intervention (level B recommendation), at either low or high dose (level B recommendation) [14] . Evidence supports a level A recommendation that vigabatrin should be the first line treatment for epileptic spasms in children with TSC [24] . According to the meta-analysis in 2012, there is insufficient evidence to recommend the use of oral corticosteroids for the short-term treatment of epileptic spasms (level U recommendation). There is weak evidence that the use of ACTH or prednisolone, in children with previously called cryptogenic aetiology may lead to an improved developmental outcome (level C recommendation) [14] , but no data specifically addressing prednisone.
Oral corticosteroids are increasingly being used off-label for the treatment of epileptic spasms [1, 14, 25] . The product is less expensive, easy to administer and readily available worldwide [26] . Prednisolone is the active form of prednisone and should not be considered as equivalent treatments for infants, who have a reduced capacity to metabolise prednisone in the first 6 months of life [27] . Prednisone is not as effective as its active form [27] . In Africa, most institutions will have access to prednisone rather than prednisolone.
Access to ACTH is limited, especially in resource-poor settings, by high cost, discomfort from injections and duration of hospitalization [18] . In the US, after Questcor acquired the rights to ACTH the price increased dramatically and since then the company has maintained the monopoly. ACTH (natural gel) costs approximately US$150 000 per treatment course compared to US $200 for prednisolone [1] . In South Africa, a 10 day course of ACTH (synthetic) costs approximately ZAR200 000 (US$17 250) and 14 day course of prednisone ZAR17 (US$1,5). Based on issues of cost and access to care in 2016 the South African Essential Drug committee removed ACTH and vigabatrin from the national code list [28] . In a setting where previously there was capacity for treatment of ES in line with international recommendations, this policy returned the country to the situation evident in most other sub-Saharan Africa settings, where the only viable agent is likely to be prednisone. As a result an urgent national and regional need arose to establish an alternate evidence based guideline for the management of ES using available agents.
Whilst there is a significant body of data for the management of ES with ACTH which supported its inclusion in guidelines and Cochrane review [14, 16] , based on the systematic review (Table 1) the same cannot be said for oral prednisone or prednisolone. Table 1 illustrates this in the summaries of the existing studies. Of the identified studies assessing the use of prednisolone, prednisone or methylprednisone there was marked variation evident in study methodologies, limiting comparison across studies. There was 1 class I study, 6 class II studies and 11 retrospective observational or uncontrolled comparative studies (class III). Six studies were based in LMICs.
Optimal cessation of spasms
Of the studies, the UKISS study was not powered enough to compare hormonal subgroups, however, prednisolone given at 40-60 mg/day resulted in a remission rate of 70% and ACTH 76% at the final clinical assessment at 14 months [20] . The difference was not significant and neither was the risk of relapse between the groups [20] . A retrospective observational class III study, by Kossoff et al (n = 15), found no statistical difference between ACTH and oral prednisolone in the resolution of spasms after 2 weeks [29] . According to Arya et al. 2 mg/kg of prednisolone was less effective compared to ACTH [25] and Chellamuthu et al concluded that a significantly higher proportion of children had spasm cessation on day 14 who had received high dose prednisolone (4 mg/kg/day) compared to those who received half the dose [18] . In the same year, Hussain et al demonstrated that very high dose prednisolone, 8 mg/kg/day, had a significantly greater efficacy than lower doses reported from previous studies [30] . O'Callaghan et al. in their 2017 report concluded that the combination of hormonal therapy and vigabatrin, was statistically more effective at stopping epileptic spasms than hormonal therapy alone. However, due to the lack of randomization of the hormonal group, it could not be determined if ACTH or prednisolone was more effective [31] .
The lack of consistency in study methodologies, directness in study questions and class I studies across reports limits forming a consensus on the evidence to support the use of prednisolone, especially as a replacement to ACTH. There was marked variation in the inclusion criteria, drop-outs, treatment lag, definition of response, proportion of low-risk/high risk, symptomatic patients, dose and duration of therapy and length of follow-up limiting comparison across studies. In addition, the optimal dose of prednisone and prednisolone still needs to be determined. For optimal care, combination therapy may be needed, as evidenced by ICISS study [31] .
In terms of other steroid formulations, 57% of patients responded to dexamethasone in a retrospective observational study by Haberlandt et al, class III study, compared to 64% to ACTH. They concluded that pulsed dexamethasone is a suitable alternative to ACTH, however, relapse rate was not stated and long term outcomes not measured [32] . More recently, a small study by Yeh et al, n = 14 class III study, concluded that short-term methylprednisolone pulsed therapy resulted in rapid resolution of epileptic spasms and hypsarrythmia without serious adverse effects [33] . There is insufficient evidence to recommend other therapies in the treatment of epileptic spasms such as valproic acid, nitrazepam, pyridoxine, zonisamide, thyrotropin-releasing hormone, topiramate, levetiracetam and ketogenic diet [14, 34] .
Adverse effects of steroids are a concern, particularly the increased risk of infections, such as tuberculosis, in LMICs, and the complications from immunodeficiency in HIV-infected infants. Other side effects include increased appetite, weight gain, hypertension, cushingoid facies, irritability, glycosuria and cerebral atrophy [14, 18] . It is advisable that prior to starting treatment, for HIV status, chest x-ray, tuberculin skin test, baseline weight and blood pressure to be recorded [18] .
Developmental outcome
According to UKISS, there was no difference in the neurodevelopmental outcome in overall data on children with ES who received hormonal treatment or vigabatrin at 14 months and 4 years of age. However, there was significant improvement in developmental scores in those who received hormonal treatment without an identifiable aetiology. [20, 21] In the same study, an increase in lag time to treatment was significantly associated with a lower developmental score at 4 years after adjusting for age of onset, aetiology and treatment [17] .
Factors that result in a more favourable long term cognitive outcome include a shorter lag time to treatment with hormonal treatment or vigabatrin (level C) [14] , shorter duration of hypsarrhythmia [35] and "cryptogenic" cause of epileptic spasms [36] . There are currently no studies assessing the long-term outcomes of children treated with prednisolone (level U recommendation).
In conclusion
Further randomised studies are needed to compare oral corticosteroids to ACTH and to determine the optimal dose, comparison efficacy, as well as long-term studies looking at the neurodevelopmental outcomes of these groups. High dose oral prednisolone appears to be evolving as a strong alternate candidate for infants with epileptic spasms, especially in settings where access to ACTH is not viable. In children with epileptic spasms and TSC vigabatrin remains the first line recommended agent. In settings where oral corticosteroids are used, standardized protocols should be in place and outcomes audited. Based on the accumulated data a recommendation has been compiled ( Fig. 1) for settings without reliable access to ACTH and vigabatrin.
Whilst there appears to be efficacy using oral corticosteroids for children with ES (level C recommendation), the optimal dose has not been defined beyond limited case series promoting higher doses. Of concern it remains unclear whether these children have a disadvantage for their relapse rate, subsequent epilepsy syndrome development and neurodevelopmental outcome.
In summary, there is class III evidence supporting a level C recommendation for the efficacy of oral corticosteroids for the acute clinical control of epileptic spasms and EEG resolution. Use of oral corticosteroids in comparison to the internationally recommended intervention of ACTH has class IV evidence resulting in a level U recommendation. Similarly, the risk of relapse with oral corticosteroids has class IV evidence and level U recommendation, and compared to ACTH, class IV evidence with level U recommendation. There is class IV evidence resulting in level U recommendation for the safety of oral corticosteroids and class II evidence supporting level B recommendation for ACTH. In terms of oral corticosteroids and effects on long-term development evidence is class IV evidence leading to level U recommendation, compared to ACTH which has class III evidence supporting level C recommendation.
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